Susquehanna International Group, LLP Caladrius Biosciences, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.74 $4,058 - $7,326	-9,900 Reduced 16.75%	49,200 $26,000
Q1 2022 May 16, 2022	BUY	$0.63 - $1.03 $20,979 - $34,299	33,300 Added 129.07%	59,100 $43,000
Q4 2021 Feb 14, 2022	BUY	$0.83 - $1.22 $5,976 - $8,784	7,200 Added 38.71%	25,800 $22,000
Q3 2021 Nov 15, 2021	SELL	$1.15 - $1.57 $143,175 - $195,465	-124,500 Reduced 87.0%	18,600 $23,000
Q2 2021 Aug 11, 2021	SELL	$1.4 - $1.9 $21,140 - $28,690	-15,100 Reduced 9.54%	143,100 $230,000
Q1 2021 May 17, 2021	BUY	$1.44 - $2.89 $199,728 - $400,843	138,700 Added 711.28%	158,200 $305,000
Q3 2020 Nov 16, 2020	SELL	$1.6 - $3.0 $10,080 - $18,900	-6,300 Reduced 24.42%	19,500 $35,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $2.38 $17,264 - $24,752	10,400 Added 67.53%	25,800 $46,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $2.99 $22,422 - $30,199	-10,100 Reduced 39.61%	15,400 $39,000
Q2 2019 Aug 14, 2019	SELL	$2.25 - $3.6 $9,000 - $14,400	-4,000 Reduced 13.56%	25,500 $58,000
Q1 2019 May 15, 2019	BUY	$3.48 - $5.32 $102,660 - $156,940	29,500 New	29,500 $107,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.